neotiv develops digital biomarkers for the early detection of neurodegenerative diseases, in particular Alzheimer´s disease. They form the basis for highly innovative cognitive tests which, embedded in a user-friendly software platform, support the detection of early-stage preclinical cognitive impairment. Being a spin-off of the Otto-von-Guericke University in Magdeburg, Germany in close collaboration with the German Centre for Neurodegenerative Diseases (DZNE), the company incorporates the latest scientific findings from the fields of neuroscience and dementia research into its technology.

http://www.neotiv.com